Report ID : 10094777 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Global Montelukast API Market Highlights Over 2022 - 2031
The global montelukast API market is estimated to grow at a CAGR of ~4% over the forecast period, i.e., 2022-2031. Additionally, the market generated notable revenue in the year 2021. The growth of the market can be attributed to control the symptoms related to urticaria, asthma, bronchospasm, allergic rhinitis, and other diseases. The various symptoms that are controlled through montelukast API include wheezing, coughing, shortness of breath, and chest tightness. Asthma affected 7.7 percent of the total population in the U.S. in 2018 as per the Centers for Disease Control and Prevention. Therefore, the number of asthma cases has increased from the past year. Moreover, there has been an increase in the aged population that are more prone to urticaria, asthma, bronchospasm, allergic rhinitis, and other diseases as compared to the younger population.
GET A SAMPLE COPY OF THIS REPORT
The COVID-19 pandemic had a positive impact on the global montelukast API market. The price of medicines increased owing to an increase in patient demand and a decrease in supply considering the government’s restriction measures. Moreover, montelukast API was used during the pandemic to control the symptoms of the disease, such as breathing problems, sneezing, and others.
The global montelukast API market is segmented by application into urticaria, asthma, bronchospasm, allergic rhinitis, and others. Out of which, the asthma segment is expected to hold the largest share in the market by the end of 2031. This can be attributed to the surge in the cases of asthma across the globe. Furthermore, there has been an increase in the percentage of world’s population dealing with asthma problems as compared to the rest of the diseases. Therefore, it is expected to increase the growth of the global montelukast API market.
Global Montelukast API Market Regional Synopsis
Regionally, the global montelukast API market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region is anticipated to have the largest market share over the forecast period owing to the presence of major pharma players. Moreover, the market in the Asia Pacific region is estimated to witness modest growth over the forecast period on the back of an increase in the number of ageing population. As per the United Nations, 60% of the world’s total population lives in the Asia region, which accounted for 4.7 billion including the world's most populous countries, China and India.
Market Segmentation
Our in-depth analysis of the global montelukast API market includes the following segments:
By Type
-
Oral Solution
-
Chewable Tablet
-
Tablet
By Application
-
Urticaria
-
Asthma
-
Bronchospasm
-
Allergic Rhinitis
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Montelukast API Market
Growth Drivers
-
Increase in the demand for montelukast for the treatment of patients to control the disease symptoms
-
Rise in the number of asthma, allergic rhinitis, urticaria, and other illness cases
Challenges
-
Increase in the side effects of montelukast in patients
Key Companies Dominating the Global Montelukast API Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global montelukast API market that are included in our report are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Vintage Pharmaceuticals, LLC (Dun & Bradstreet, Inc.), SANYO CHEMICAL INDUSTRIES, LTD., Mylan (Viatris Inc.), Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Cipla Inc., and others.
Latest Developments in the Global Montelukast API Market:
-
28 November 2020: In Russia, Ukraine, Kazakhstan, and Uzbekistan, Dr. Reddy's Laboratories Ltd. purchased select Glenmark anti-allergy brands through an agreement with Glenmark Pharmaceuticals Ltd.
-
25 January 2022: Merck & Co., Inc., announced the completion of its acquisition of Themis, a company specializing in immune modulation therapies and infectious disease vaccines.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the client's requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
